Oct. 6, 2021 Price forecast | 2 weeks: -1.70% | 1 month: -3.62% | 3 months: -7.25%


ADPT stock forecast

Our latest prediction for Adaptive Biotechnologies Corp's stock price was made on the Oct. 6, 2021 when the stock price was at 32.17$.

In the short term (2weeks), ADPT's stock price should underperform the market by -1.70%. During that period the price should oscillate between -9.29% and +8.83%.

In the medium term (3months), ADPT's stock price should underperform the market by -7.25%. During that period the price should oscillate between -32.26% and +20.34%.

Create a solid portfolio with ADPT

Add ADPT to your portfolio and optimize it!


About Adaptive Biotechnologies Corp

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

At the moment the company generates 133M USD in revenues.

On its last earning announcement, the company reported a loss of -1.24$ per share.

The book value per share is 2.38$

Adaptive Biotechnologies Corp website


Three months stock forecastOct. 6, 2021


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
133M 75.20% -172M -129.19% -171M -1.24 - - 138M 2.38 -182M -51M -234M